732 related articles for article (PubMed ID: 32001798)
21. Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma.
Chari A; Martinez-Lopez J; Mateos MV; Bladé J; Benboubker L; Oriol A; Arnulf B; Rodriguez-Otero P; Pineiro L; Jakubowiak A; de Boer C; Wang J; Clemens PL; Ukropec J; Schecter J; Lonial S; Moreau P
Blood; 2019 Aug; 134(5):421-431. PubMed ID: 31113777
[TBL] [Abstract][Full Text] [Related]
22. 3-weekly daratumumab-lenalidomide/pomalidomide-dexamethasone is highly effective in relapsed and refractory multiple myeloma.
Chim CS; Kumar S; Wong VKC; Ngai C; Kwong YL
Hematology; 2021 Dec; 26(1):652-655. PubMed ID: 34474661
[TBL] [Abstract][Full Text] [Related]
23. Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials.
Mateos MV; Goldschmidt H; San-Miguel J; Mikhael J; DeCosta L; Zhou L; Obreja M; Blaedel J; Szabo Z; Leleu X
Hematol Oncol; 2018 Apr; 36(2):463-470. PubMed ID: 29446103
[TBL] [Abstract][Full Text] [Related]
24. Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment.
Siegel DS; Schiller GJ; Samaras C; Sebag M; Berdeja J; Ganguly S; Matous J; Song K; Seet CS; Talamo G; Acosta-Rivera M; Bar M; Quick D; Anz B; Fonseca G; Reece D; Pierceall WE; Chung W; Zafar F; Agarwal A; Bahlis NJ
Leukemia; 2020 Dec; 34(12):3286-3297. PubMed ID: 32376855
[TBL] [Abstract][Full Text] [Related]
25. Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients.
Nooka AK; Joseph NS; Kaufman JL; Heffner LT; Gupta VA; Gleason C; Boise LH; Lonial S
Cancer; 2019 Sep; 125(17):2991-3000. PubMed ID: 31090928
[TBL] [Abstract][Full Text] [Related]
26. Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups.
Orlowski RZ; Moreau P; Niesvizky R; Ludwig H; Oriol A; Chng WJ; Goldschmidt H; Yang Z; Kimball AS; Dimopoulos M
Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):522-530.e1. PubMed ID: 31160237
[TBL] [Abstract][Full Text] [Related]
27. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
Attal M; Richardson PG; Rajkumar SV; San-Miguel J; Beksac M; Spicka I; Leleu X; Schjesvold F; Moreau P; Dimopoulos MA; Huang JS; Minarik J; Cavo M; Prince HM; Macé S; Corzo KP; Campana F; Le-Guennec S; Dubin F; Anderson KC;
Lancet; 2019 Dec; 394(10214):2096-2107. PubMed ID: 31735560
[TBL] [Abstract][Full Text] [Related]
28. Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment.
Dimopoulos MA; Stewart AK; Masszi T; Špička I; Oriol A; Hájek R; Rosiñol L; Siegel D; Mihaylov GG; Goranova-Marinova V; Rajnics P; Suvorov A; Niesvizky R; Jakubowiak A; San-Miguel J; Ludwig H; Ro S; Aggarwal S; Moreau P; Palumbo A
Blood Cancer J; 2017 Apr; 7(4):e554. PubMed ID: 28430175
[TBL] [Abstract][Full Text] [Related]
29. Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial.
Mateos MV; Hernández MT; Giraldo P; de la Rubia J; de Arriba F; Corral LL; Rosiñol L; Paiva B; Palomera L; Bargay J; Oriol A; Prosper F; López J; Arguiñano JM; Quintana N; García JL; Bladé J; Lahuerta JJ; Miguel JS
Lancet Oncol; 2016 Aug; 17(8):1127-1136. PubMed ID: 27402145
[TBL] [Abstract][Full Text] [Related]
30. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study.
Dimopoulos M; Quach H; Mateos MV; Landgren O; Leleu X; Siegel D; Weisel K; Yang H; Klippel Z; Zahlten-Kumeli A; Usmani SZ
Lancet; 2020 Jul; 396(10245):186-197. PubMed ID: 32682484
[TBL] [Abstract][Full Text] [Related]
31. Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma.
Chari A; Cornell RF; Gasparetto C; Karanes C; Matous JV; Niesvizky R; Lunning M; Usmani SZ; Anderson LD; Chhabra S; Girnius S; Shustik C; Stuart R; Lee Y; Salman Z; Liu E; Valent J
Hematol Oncol; 2020 Aug; 38(3):353-362. PubMed ID: 32053229
[TBL] [Abstract][Full Text] [Related]
32. FDA Approval Summary: Daratumumab for Treatment of Multiple Myeloma After One Prior Therapy.
Bhatnagar V; Gormley NJ; Luo L; Shen YL; Sridhara R; Subramaniam S; Shen G; Ma L; Shord S; Goldberg KB; Farrell AT; McKee AE; Pazdur R
Oncologist; 2017 Nov; 22(11):1347-1353. PubMed ID: 28904172
[TBL] [Abstract][Full Text] [Related]
33. Comparative Efficacy of Treatments for Previously Treated Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis.
Maiese EM; Ainsworth C; Le Moine JG; Ahdesmäki O; Bell J; Hawe E
Clin Ther; 2018 Mar; 40(3):480-494.e23. PubMed ID: 29500140
[TBL] [Abstract][Full Text] [Related]
34. A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial.
Hou J; Du X; Jin J; Cai Z; Chen F; Zhou DB; Yu L; Ke X; Li X; Wu D; Meng F; Ai H; Zhang J; Wortman-Vayn H; Chen N; Mei J; Wang J
J Hematol Oncol; 2013 Jun; 6():41. PubMed ID: 23782711
[TBL] [Abstract][Full Text] [Related]
35. Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II study.
Chari A; Rodriguez-Otero P; McCarthy H; Suzuki K; Hungria V; Sureda Balari A; Perrot A; Hulin C; Magen H; Iida S; Maisnar V; Karlin L; Pour L; Parasrampuria DA; Masterson T; Kosh M; Yang S; Delioukina M; Qi M; Carson R; Touzeau C
Br J Haematol; 2021 Mar; 192(5):869-878. PubMed ID: 33216361
[TBL] [Abstract][Full Text] [Related]
36. Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.
Richardson PG; Kumar SK; Masszi T; Grzasko N; Bahlis NJ; Hansson M; Pour L; Sandhu I; Ganly P; Baker BW; Jackson SR; Stoppa AM; Gimsing P; Garderet L; Touzeau C; Buadi FK; Laubach JP; Cavo M; Darif M; Labotka R; Berg D; Moreau P
J Clin Oncol; 2021 Aug; 39(22):2430-2442. PubMed ID: 34111952
[TBL] [Abstract][Full Text] [Related]
37. Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma.
Baertsch MA; Schlenzka J; Mai EK; Merz M; Hillengaß J; Raab MS; Hose D; Wuchter P; Ho AD; Jauch A; Hielscher T; Kunz C; Luntz S; Klein S; Schmidt-Wolf IG; Goerner M; Schmidt-Hieber M; Reimer P; Graeven U; Fenk R; Salwender H; Scheid C; Nogai A; Haenel M; Lindemann HW; Martin H; Noppeney R; Weisel K; Goldschmidt H
BMC Cancer; 2016 Apr; 16():290. PubMed ID: 27114074
[TBL] [Abstract][Full Text] [Related]
38. Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE.
San-Miguel J; Avet-Loiseau H; Paiva B; Kumar S; Dimopoulos MA; Facon T; Mateos MV; Touzeau C; Jakubowiak A; Usmani SZ; Cook G; Cavo M; Quach H; Ukropec J; Ramaswami P; Pei H; Qi M; Sun S; Wang J; Krevvata M; DeAngelis N; Heuck C; Van Rampelbergh R; Kudva A; Kobos R; Qi M; Bahlis NJ
Blood; 2022 Jan; 139(4):492-501. PubMed ID: 34269818
[TBL] [Abstract][Full Text] [Related]
39. Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.
Chari A; Suvannasankha A; Fay JW; Arnulf B; Kaufman JL; Ifthikharuddin JJ; Weiss BM; Krishnan A; Lentzsch S; Comenzo R; Wang J; Nottage K; Chiu C; Khokhar NZ; Ahmadi T; Lonial S
Blood; 2017 Aug; 130(8):974-981. PubMed ID: 28637662
[TBL] [Abstract][Full Text] [Related]
40. Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom).
Knop S; Gerecke C; Liebisch P; Topp MS; Platzbecker U; Sezer O; Vollmuth C; Falk K; Glasmacher A; Maeder U; Einsele H; Bargou RC
Blood; 2009 Apr; 113(18):4137-43. PubMed ID: 19182205
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
